Ge Wei

USPTO Granted Patents = 24 (Patent Applications = 16)

CIPO Patents = 4 (Patent Applications = 1)

EPO Patents = 4 (Patent Applications = 9)

Average Co-Inventor Count = 4.1

ph-index = 6

Forward Citations = 129(Granted Patents)

Company Filing History:

Years Active: 2015-2025

Loading Chart...

24 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12371685 - PH20 polypeptide variants with a modification at position 324 of the PH20 polypeptide and a method of making thereof (2025-07-29),

2. 12264345 - PH20 polypeptide variants, formulations and uses thereof (2025-04-01),

3. 12195773 - PH20 polypeptide variants, formulations and uses thereof (2025-01-14),

4. 12152262 - PH20 polypeptide variants, formulations and uses thereof (2024-11-26),

5. 12123035 - PH20 polypeptide variants, formulations and uses thereof (2024-10-22),

6. 12110520 - PH20 polypeptide variants, formulations and uses thereof (2024-10-08),

7. 12104185 - PH20 polypeptide variants, formulations and uses thereof (2024-10-01),

8. 12104184 - PH20 polypeptide variants, formulations and uses thereof (2024-10-01),

9. 12091692 - PH20 polypeptide variants, formulations and uses thereof (2024-09-17),

10. 12077791 - PH20 polypeptide variants with a modification at position 309 of the PH20 polypeptide and a method of making thereof (2024-09-03),

11. 12060590 - PH20 polypeptide variants, formulations and uses thereof (2024-08-13),

12. 12054758 - PH20 polypeptide variants, formulations and uses thereof (2024-08-06),

13. 12049652 - PH20 polypeptide variants, formulations and uses thereof (2024-07-30),

14. 12037618 - PH20 polypeptide variants, formulations and uses thereof (2024-07-16),

15. 12018298 - PH20 polypeptide variants, formulations and uses thereof (2024-06-25),

Title: Ge Wei: Innovator in Hyaluronidase Polypeptides

Introduction: Ge Wei is a noteworthy inventor based in San Diego, California, recognized for his significant contributions to the field of biochemistry and pharmaceuticals. With a remarkable portfolio of 22 patents, Ge has made advancements that are pushing the boundaries of therapeutic innovations.

Latest Patents: Among his latest patents are developments related to PH20 polypeptide variants and formulations. His work includes modified PH20 hyaluronidase polypeptides that demonstrate enhanced stability and increased activity. These innovations not only pave the way for improved compositions but also expand the potential applications in various therapeutic areas.

Career Highlights: Ge Wei has built an impressive career working with reputable companies such as Halozyme, Inc. and Ignyta, Inc. His roles in these organizations have facilitated impactful research and development that contribute to the healthcare sector. His extensive patent portfolio reflects his expertise and dedication to advancing biotechnological innovations.

Collaborations: Throughout his career, Ge Wei has collaborated with several talented professionals, including Qiping Zhao and Robert James Connor. These partnerships have enriched his research and fostered a collaborative environment, leading to groundbreaking discoveries in polypeptide research.

Conclusion: Ge Wei's contributions to the development of modified PH20 hyaluronidase polypeptides illustrate his commitment to innovation in the pharmaceutical industry. As he continues to push the frontiers of research, his work stands as an inspiration for both current and future inventors in the field.

This text is generated by artificial intelligence and may not be accurate.